Hanseatic Management Services Inc. grew its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 14.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,334 shares of the biotechnology company’s stock after acquiring an additional 298 shares during the quarter. Hanseatic Management Services Inc.’s holdings in bluebird bio were worth $416,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its position in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares in the last quarter. NuWave Investment Management LLC purchased a new position in bluebird bio during the fourth quarter worth $135,000. Ladenburg Thalmann Financial Services Inc. increased its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares in the last quarter. Biondo Investment Advisors LLC purchased a new position in bluebird bio during the third quarter worth $203,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in bluebird bio during the second quarter worth $211,000.
In related news, insider Jason Cole sold 1,129 shares of bluebird bio stock in a transaction on Friday, January 5th. The stock was sold at an average price of $173.38, for a total value of $195,746.02. Following the transaction, the insider now owns 19,945 shares in the company, valued at $3,458,064.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Davidson sold 6,000 shares of bluebird bio stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total value of $1,081,800.00. Following the completion of the transaction, the insider now owns 21,977 shares in the company, valued at approximately $3,962,453.10. The disclosure for this sale can be found here. Insiders sold 182,098 shares of company stock worth $33,999,709 in the last quarter. 3.90% of the stock is owned by insiders.
bluebird bio Inc (NASDAQ:BLUE) opened at $233.05 on Tuesday. bluebird bio Inc has a fifty-two week low of $74.45 and a fifty-two week high of $234.90.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The firm had revenue of $4.17 million during the quarter, compared to analyst estimates of $7.11 million. During the same quarter in the previous year, the business posted ($1.88) EPS. bluebird bio’s revenue was up 169.0% compared to the same quarter last year. research analysts forecast that bluebird bio Inc will post -8.25 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/03/13/hanseatic-management-services-inc-buys-298-shares-of-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.